Marker
(% cells) |
Healthy donors (n=13) |
TB patients |
The total group
( n=27) |
PPD-responsive
(n=17) |
PPD-anergic
(n=10 ) |
| CD14+ |
8.7 ± 1.4 |
19.6 ± 2.5 * |
17.2 ± 2.7 * |
30.0 ± 5.4 *# |
| CD25+ |
25.1 ± 3.5 |
9.6 ± 1.2 * |
8.8 ± 1.3 * |
12.1 ± 2.9 * |
| CD1a+ |
11.8 ± 2.5 |
11.8 ± 1.4 |
10.7 ± 1.4 |
14.6 ± 3.7 |
| CD83+ |
23.3 ± 2.7 |
32.4 ± 2.9 |
34.2 ± 3.7 |
27.8 ± 3.4 |
| CD11c+ |
28.3 ± 2.6 |
30.2 ± 2.7 |
29.5 ± 3.2 |
34.2 ± 5.3 |
| CD123+ |
27.5 ± 2.3 |
25.2 ± 1.8 |
24.0 ± 2.0 |
25.0 ± 2.7 |
| CD1a+CD83- |
6.9 ± 2.0 |
5.3 ± 0.8 |
4.5 ± 0.7 |
7.5 ± 2.0 |
| CD1a+CD83+ |
5.0 ± 1.0 |
6.5 ± 1.0 |
6.2 ± 1.1 |
7.1 ± 2.3 |
| CD1a-CD83+ |
18.9 ± 2.6 |
25.9 ± 2.8 |
28.0 ± 3.6 |
20.7 ± 2.9 |
Note: Analysis of IFN-DC phenotype was performed by one- or two-color flow cytometry assays using FITC-, PE- or APC-conjugated antibodies (CD1a, CD11c, CD14, CD25, CD83, CD123; Pharmingen, USA). * - pU <0.05 vs healthy donors; # - pU <0.05 vs PPD-responsive patients. |
